Essential thrombocythemia treatment algorithm 2018

Ayalew Tefferi, Alessandro M. Vannucchi, Tiziano Barbui

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. Fortunately, prognosis in ET and PV is relatively good, with median survivals in younger patients estimated at 33 and 24 years, respectively. Therefore, when it comes to treatment in ET or PV, less is more and one should avoid exposing patients to new drugs that have not been shown to be disease-modifying, and whose long-term consequences are suspect (e.g., ruxolitinib). Furthermore, the main indication for treatment in ET and PV is to prevent thrombosis and, in that regard, none of the newer drugs have been shown to be superior to the time-tested older drugs (e.g., hydroxyurea). We currently consider three major risk factors for thrombosis (history of thrombosis, JAK2/MPL mutations, and advanced age), in order to group ET patients into four risk categories: "very low risk" (absence of all three risk factors); "low risk" (presence of JAK2/MPL mutations); "intermediate-risk" (presence of advanced age); and "high-risk" (presence of thrombosis history or presence of both JAK2/MPL mutations and advanced age). Herein, we provide a point-of-care treatment algorithm that is risk-adapted and based on evidence and decades of experience.

Original languageEnglish (US)
Article number2
JournalBlood cancer journal
Issue number1
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Essential thrombocythemia treatment algorithm 2018'. Together they form a unique fingerprint.

Cite this